Acacia

Q4 2025 +20.72%Q3 2025 +9.42%Q2 2025 -8.96%Q1 2025 +15.74%Q4 2024 -14.45%Q3 2024 -8.88%Q2 2024 -4.78%Q1 2024 -1.93%Q4 2023 +16.25%Q3 2023 +1.65%Q2 2023 -7.23%Q1 2023 -1.25%Q4 2022 -7.49%Q3 2022 +2.03%Q2 2022 -2.99%Q1 2022 -3.87%Q4 2021 +12.34%Q3 2021 +5.26%Q2 2021 -4.87%Q1 2021 -5.11%Q4 2020 +0.66%Q3 2020 +1.39%Q2 2020 -0.97%Q1 2020 -0.20%Q4 2019 +3.60%Q3 2019 +14.18%Q2 2019 -3.59%Q1 2019 +0.96%Q4 2018 -3.17%Q3 2018 +2.68%Q2 2018 +2.63%Q1 2018 +1.37%Q4 2017 -1.39%Q3 2017 +6.10%Q2 2017 -10.00%Q1 2017 -4.90%Q4 2016 -9.57%Q3 2016 +1.68%Q2 2016 +7.55%Q1 2016 +4.07%Q4 2015 -21.78%Q3 2015 -14.35%Q2 2015 +9.07%Q1 2015 +12.92%Q4 2014 -3.61%Q3 2014 +1.18%Q2 2014 +16.83%Q1 2014 -0.19%Q4 2013 -6.12%Q3 2013 -25.25%Q2 2013 -12.41%Q1 2013 -27.20%Q4 2012 +3.84%Q3 2012 -0.16%Q2 2012 +1.09%Q1 2012 +2.27%Q1 2010 -2.89%Q1 2011 -2.89%Q4 2009 -2.89%Q4 2011 -2.89%Q3 2010 -6.94%Q3 2011 -6.94%Q2 2010 -1.77%Q2 2011 -1.77%Q4 2010 -1.77%

May 17, 2021

•

Mar 31, 2021

Acacia Q1 2021 Earnings Report

Acacia Research reported financial results for the first quarter of 2021.

Key Takeaways

Acacia Research reported its Q1 2021 financial results, with a focus on evaluating new strategic opportunities and ongoing IP investments. The company led the reconstitution of the Board of Directors of Arix Bioscience plc, where Acacia is a significant shareholder.

Ongoing evaluation of new strategic opportunities in collaboration with Starboard Value LP.

Focus on acquiring operating companies in mature technology, healthcare, industrial, and financial services segments.

IP investments have resulted in a balanced portfolio.

Led the reconstitution of the Board of Directors of Arix Bioscience plc.

Total Revenue

$5.8M

Previous year: $3.82M

+52.1%

EPS

-$2.81

Previous year: -$0.24

+1070.8%